<DOC>
	<DOCNO>NCT00125463</DOCNO>
	<brief_summary>The purpose study compare angiotensin II receptor antagonist ( candesartan cilexetil– Blopress® ) calcium channel blocker ( amlodipine besilate– Norvasc®/Amlodin® ) term incidence cardiovascular event among high-risk hypertensive patient .</brief_summary>
	<brief_title>Candesartan Antihypertensive Survival Evaluation Japan ( CASE-J ) Trial Cardiovascular Events High-Risk Hypertensive Patients</brief_title>
	<detailed_description>Hypertension continue major public health issue world . To combat problem , many antihypertensive drug develop proven effective control blood pressure last half century . In recent decade , antihypertensive drug show cardiovascular benefit beyond reduction blood pressure , focus shift clarification effect . Angiotensin II receptor antagonist calcium channel blocker widely use antihypertensive drug Japan . However , two class drug yet compare respect efficacy treat cardiovascular event . Comparison : Response-dependent dose titration blind assessment endpoint high risk hypertensive patient treat either angiotensin II receptor antagonist ( candesartan cilexetil ) compare third-generation calcium channel blocker ( amlodipine besilate ) .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<criteria>Systolic blood pressure ( SBP ) ≥140 mmHg ＜70 year old ≥160 mmHg ≥70 year old diastolic blood pressure ( DBP ) ≥90 mmHg sit position two consecutive measurement clinic At least one follow risk factor : SBP ≥180 mmHg DBP ≥110 mmHg two consecutive visit ; Type 2 diabetes ( fast blood glucose ≥126 mg/dl , causal blood glucose ≥200 mg/dl , HbA1c ≥6.5 % , 2 hour blood glucose 75 g oral glucose tolerance test [ OGTT ] ≥200 mg/dl , current treatment hypoglycemic agent ) ; History cerebral hemorrhage , cerebral infarction , transient ischemic attack 6 month prior screen ; Thickness posterior wall leave ventricle thickness wall interventricular septum ≥12 mm echocardiography Sv1＋Rv5 ≥35 mm electrocardiography , angina pectoris , past history ( ≥6 month give informed consent ) myocardial infarction ; Proteinuria ≥＋1 renal impairment ( serum creatinine ≥1.3 mg/dl ) within 3 month time give informed consent ; Arteriosclerotic peripheral arterial obstruction ( Fontaine class ≥2 ) ; *Clinical diagnosis Alzheimer 's disease . SBP ≥200 mmHg DBP ≥120 mmHg sit position Type I diabetes mellitus History myocardial infarction cerebrovascular accident within 6 month prior screen Percutaneous transluminal coronary angioplasty ( PTCA ) coronary artery bypass grafting ( CABG ) do within 6 month screen schedule Current treatment congestive cardiac failure ( New York Heart Association [ NYHA ] functional class II severer ) ejection fraction ＜40 % Coronary artery disease require αβ blocker calcium channel blocker Atrial fibrillation atrial flutter Renal dysfunction ( serum creatinine ≥3 mg/dl ) Hepatic dysfunction ( AST and/or ALT ≥100 IU/l ) A history malignant tumor within 5 year enrollment suspect Contraindication candesartan cilexetil amlodipine besilate Pregnancy , possible pregnancy , plan conceive child within 5 year enrollment Not suit clinical trial judge collaborate physician Inability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2005</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>clinical trial</keyword>
	<keyword>Candesartan Antihypertensive Survival Evaluation Japan trial</keyword>
	<keyword>candesartan cilexetil</keyword>
	<keyword>amlodipine besilate</keyword>
</DOC>